







Research Article

Assessment of Antibiotic Resistance and Efflux Pump Gene Expression in *Neisseria Gonorrhoeae* Isolates from South Africa by Quantitative Real-Time PCR and Regression Analysis

Nireshni Mitchev ¹, Ravesh Singh ^{1,2}, Veron Ramsuran ¹, Arshad Ismail ^{3,4},
Mushal Allam ^{3,5}, Stanford Kwenda ³, Florah Mnyameni ³, Nigel Garrett ^{6,7},
Khine Swe Swe-Han ^{1,2}, Abraham J. Niehaus ¹ and Koleka P. Mlisana ^{1,6,8}

¹School of Laboratory Medicine and Medical Sciences, University of KwaZulu Natal (UKZN), Durban, South Africa

²National Health Laboratory Service, Durban, South Africa

³Sequencing Core Facility, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa

⁴Department of Biochemistry and Microbiology, Faculty of Science Engineering and Agriculture, University of Venda, Thohoyandou, South Africa

⁵Department of Genetics and Genomics, United Arab Emirates University, Al Ain, UAE

⁶Centre for the AIDS Programme of Research in South Africa, Durban, South Africa

⁷School of Nursing and Public Health, UKZN, Durban, South Africa

⁸National Health Laboratory Service, Johannesburg, South Africa

Correspondence should be addressed to Nireshni Mitchev; nireshninaidoo@live.co.za

Received 26 January 2022; Revised 6 September 2022; Accepted 28 September 2022; Published 21 October 2022

Academic Editor: Todd R. Callaway

Copyright © 2022 Nireshni Mitchev et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. Treatment of gonorrhoea infection is limited by the increasing prevalence of multidrug-resistant strains. Cost-effective molecular diagnostic tests can guide effective antimicrobial stewardship. The aim of this study was to correlate mRNA expression levels in *Neisseria gonorrhoeae* antibiotic target genes and efflux pump genes to antibiotic resistance in our population. **Methods.** This study investigated the expression profile of antibiotic resistance-associated genes (*penA*, *ponA*, *pilQ*, *mtrR*, *mtrA*, *mtrF*, *gyrA*, *parC*, *parE*, *rpsJ*, 16S rRNA, and 23S rRNA) and efflux pump genes (*macAB*, *norM*, and *mtrCDE*), by quantitative real-time PCR, in clinical isolates from KwaZulu-Natal, South Africa. Whole-genome sequencing was used to determine the presence or absence of mutations. **Results.** *N. gonorrhoeae* isolates, from female and male patients presenting for care at clinics in KwaZulu-Natal, South Africa, were analysed. As determined by binomial regression and ROC analysis, the most significant ($p \leq 0.05$) markers for resistance prediction in this population, and their cutoff values, were determined to be *mtrC* ($p = 0.024$; cutoff < 0.089), *gyrA* ($p = 0.027$; cutoff < 0.0518), *parE* ($p = 0.036$; cutoff < 0.0033), *rpsJ* ($p = 0.047$; cutoff < 0.0012), and 23S rRNA ($p = 0.042$; cutoff > 7.754). **Conclusion.** Antimicrobial stewardship includes exploring options to conserve currently available drugs for gonorrhoea treatment. There is the potential to predict an isolate as either susceptible or nonsusceptible based on the mRNA expression level of specific candidate markers, to inform patient management. This real-time qPCR approach, with few targets, can be further investigated for use as a potentially cost-effective diagnostic tool to detect resistance.

1. Introduction

Increasing antimicrobial resistance (AMR) to *Neisseria gonorrhoeae* is now a public health priority [1, 2] as it threatens the current World Health Organization

(WHO) recommended dual therapy (ceftriaxone and azithromycin) [1–3]. Molecular mechanisms of drug resistance have been well characterized [4, 5] and are mainly due to mutational alterations of the drug target, plasmids, and efflux pumps [6, 7].

Globally, 87 million new cases of the sexually transmitted infection (STI) gonorrhoea occur annually, where the highest prevalence has been reported in the WHO Africa region [8]. The estimated prevalence of gonorrhoea in African countries was reported to be 1.4%–15.2%, with higher prevalence in high-risk groups (sex-workers and participants recruited from venues considered to have a higher probability for acquiring infection, e.g., bars) [9]. South Africa has an estimated prevalence of ~5% [9, 10]. *N. gonorrhoeae* infections are usually localized to the mucosal surfaces of the hosts initial exposure to the organism [11, 12]. Infection of the male urethra causes urethritis (inflammation of the urethra), the symptoms of which, include purulent discharge and dysuria [13]. While male urethritis commonly produces symptoms, gonorrhoea in women is often asymptomatic [14]. The sequelae of untreated gonorrhoea includes acute urethritis, cervicitis, pelvic inflammatory disease (PID), infertility, abortion, ectopic pregnancy, maternal death, and neonatal blindness [15–19].

In Africa and other resource-limited settings, syndromic management of patients remains the main STI management model. Syndromic and empiric treatment leads to over-treatment [20] and contributes to the development of resistance to currently recommended drugs in many parts of the world [21–24]. There is no vaccine for gonorrhoea yet; thus, its prevention and control depends on an accurate diagnosis and appropriate antimicrobial therapy [25]. Currently, treatment options are few and antimicrobial stewardship programmes can reduce antibiotic resistance [26]. There is an urgent need for rapid diagnostic tools to direct therapy [27, 28].

The AMR mechanisms via which *N. gonorrhoeae* has developed resistance has been thoroughly reviewed [4, 29]. These include antimicrobial inactivation, alteration of target sites, increased export via efflux pumps, and decreased uptake via porins [29]. Resistance-to-penicillin and extended-spectrum cephalosporins (ESC) have been associated with modifications and recombination within *penA*, *porB*, *ponA* [30], and the presence of *bla*_{TEM} plasmid (penicillin) [4, 31]. Modifications in *penA* result in decreased affinity for penicillin, and recombination with *penA* genes from commensal *Neisseria* species has led to the development of mosaic *penA* alleles which causes resistance-to-penicillin, cefixime, and ceftriaxone [4, 32, 33]. The mutation L421P in *ponA* reduces the rate of acylation with penicillin [34]. Mutations in *porB*, which encode porinB, reduce the porin permeability, which then reduces penicillin influx [4]. The *bla*_{TEM-1} gene is responsible for plasmid-mediated resistance-to-penicillin, and a previous study from South Africa showed a prevalence of 66% in nonsusceptible isolates [35]. Mutations in *mtrR*, as well as its promoter region, can cause overexpression of the MtrCDE efflux pump, which has been associated with resistance-to-hydrophobic agents (penicillin, cefixime, ceftriaxone, and azithromycin) [36]. Pore formation in the outer membrane is encoded for by the *pilQ* gene, mutations in this gene result in reduced antibiotic influx

and high-level resistance-to-penicillin [4, 12, 37–39]. When treating patients with an antibiotic, low-level resistance means that an increased dose of the antibiotic can still overcome the resistance to it and clear the infection. High-level resistance, however, means that even an increased dose will not be able to clear the infection i.e., the antibiotic should not be used.

Resistance to tetracycline has been associated with the presence of tetM and mutations in *rpsJ*, *mtrR*, and *porB* [36]. The tetM gene confers high-level plasmid-mediated resistance-to-tetracycline by binding to the 30S ribosomal subunit, thus, releasing the tetracycline molecule and protein synthesis continues [40]. Chromosomally mediated resistance is due to the ribosomal subunit being modified, thus, increasing the efflux and decreasing the influx of tetracycline [4]. The *rpsJ* mutation V57M, alters the binding site, thus, reducing binding affinity of tetracycline for the ribosome [41]. As described for penicillin, modifications in *mtrR* and *porB*, which result in reduced drug accumulation, also contribute to resistance-to-tetracycline [4, 12, 42].

Resistance to ciprofloxacin is due to mutations in *gyrA* and *parC* [36], and mutations in the *norM* promoter results in overexpression of NorM efflux pump, which increases ciprofloxacin MICs [4, 7, 43]. Quinolones inhibit DNA gyrase (encoded by *gyrA* and *gyrB*) and topoisomerase IV (encoded by *parC* and *parE*), which are essential for DNA metabolism, resulting in bactericidal activity [4]. Mutations in these genes alter quinolone recognition of the enzymes and result in resistance [4, 29]. Although many mutations have been identified in *gyrA* and *parC*, the key mutations responsible for quinolone resistance include *gyrA*_S91F, *gyrA*_D95N, *parC*_S88P, and *parC*_E91K [4, 5, 44]. Mutations in the *gyrB* and *parE* genes did not significantly impact resistance-to-ciprofloxacin. Mutation in the *norM* promoter results in overexpression of the NorM efflux pump, which decreases ciprofloxacin susceptibility MICs [4, 45].

High-level resistance-to-spectinomycin is due to the mutation C1192U in 16S rRNA by reducing target affinity [42]. Resistance-to-azithromycin is often due to mutations in 23S rRNA, namely C2611T (low-level resistance) or A2059 (high-level resistance) [4, 42]. Mutation in the promoter regions of MacAB and *mef*-encoded efflux pumps result in overexpression contributing to resistance-to-macrolides [4, 7, 42, 43, 46].

A range of molecular diagnostic approaches have been evaluated, each with its strengths and limitations [42, 47–51]. While most methods target specific mutations to infer resistance, our approach targets the gene and its expression levels to infer resistance. Genomics prediction tools and equations have been extremely effective in characterizing antimicrobial resistance mechanisms [52, 53]. At present, ResistancePlus® GC (SpeeDx Pty Ltd, Sydney, Australia), which detects resistance-to-ciprofloxacin, is the only commercially available genotypic resistance testing assay for *N. gonorrhoeae*. The assay uses real-time PCR to detect species-specific *porA* and *opa* genes for identification and differentiates the *gyrA*_S91 wild type

from the *gyrA*_S91F mutant to determine susceptibility or resistance-to-ciprofloxacin. In populations where the resistance-to-ciprofloxacin is high, assays which predict resistance to additional drugs would be beneficial.

The aim of this study was to correlate mRNA expression levels in *N. gonorrhoeae* antibiotic target genes and efflux pump genes to antibiotic resistance in our population using real-time qPCR, a cost-effective alternative to WGS. A secondary objective was to determine from isolates, if any genes are expressed more in either gender.

2. Materials and Methods

2.1. Source of Isolates. All 110 *N. gonorrhoeae* isolates in this study were stored and analysed at the University of KwaZulu-Natal Department of Medical Microbiology. The specimens were collected between 2013 and 2016 from male and female patients attending KZN public healthcare clinics for STI care during ethics approved studies. Ethical approval for this study was granted by the Biomedical Research Ethics Committee of the University of KwaZulu-Natal BREC/00000097/2019.

2.2. Identification of *Neisseria gonorrhoeae*. Stored *N. gonorrhoeae* isolates (vaginal and urethral specimens) were revived on nonselective Thayer Martin media (supplemented with 1% Vitox, excluding antibiotic supplements) for 18–24 hours in a 37°C 5% CO₂ incubator. Identification was confirmed (supplementary Table 1 and supplementary Figure 1) using bright field microscopy (*N. gonorrhoeae* is a Gram-negative diplococcus), Bactident® Oxidase rapid test (Merck, Germany) (*N. gonorrhoeae* is oxidase positive), and Phadebact® Monoclonal GC test (Pharmacia, Sweden) (a coagglutination technique used for the definitive identification of *N. gonorrhoeae*) [11, 13, 54]. In addition, a real-time PCR assay, *N. gonorrhoeae* TaqMan® probe Ba046466252 (Thermo Scientific) was used for molecular identification. A subset of 61 male and female isolates with similar antibiotic profiles were selected for WGS. This data confirmed the identification of *N. gonorrhoeae* using Kraken [55] and Pathogenwatch [56].

2.3. Phenotypic Antibiotic Susceptibility Testing. Antimicrobial susceptibility testing was performed, using Etest® (bioMérieux, Marcy l'Etoile, France), for all isolates, using GC agar base medium (used for the isolation and cultivation of *N. gonorrhoeae*) supplemented with 1% Vitox (Oxoid) [57–59]. The minimum inhibitory concentration (MIC) was determined as the lowest concentration of the drug to visually inhibit the growth of the organism. The drugs and concentration ranges were as follows; penicillin (0.016–256 µg/mL), ciprofloxacin (0.002–32 µg/mL), ceftriaxone (0.002–32 µg/mL), cefixime (0.016–256 µg/mL), spectinomycin (0.064–1024 µg/mL), tetracycline (0.016–256 µg/mL), and azithromycin (0.016–256 µg/mL). Susceptibility was interpreted as per the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines [60]. Nitrocefin (a chromogenic cephalosporin

substrate) was used to detect β-lactamase production, which indicates resistance to beta-lactam antibiotics such as penicillin [61]. The 2016 WHO gonococcal reference strains (F, G, K, L, M, N, O, P, U, V, W, X, Y, Z) [62] and ATCC 49226 were used as controls in this study.

2.4. Whole-Genome Sequencing and Assembly. DNA was extracted using the PureLink™ Microbiome DNA Purification Kit (ThermoFisher Scientific) as per the manufacturer's instructions. Paired-end libraries were prepared using the Nextera DNA Prep kit, followed by sequencing (2 × 75 bp) on a NextSeq platform (Illumina, Inc., USA). Raw paired-end (PE) reads were initially run through the Jekesa pipeline v1.0 [63] for WGS bacterial typing. Briefly, Trim Galore v0.6.2 [64]; was used to filter the PE reads (Q > 30 and length > 50 bp). *De novo* assembly and polishing of assemblies were performed using SPAdes v.3.13 [65] and Shovill v1.1.0 [66], respectively. Assembly metrics were calculated using QUAST v5.0.2 [67]. AMR markers were identified using PointFinder [68] and confirmed using Pathogenwatch [69] and Clustal Omega [70]. Whole-genome sequence data is available in DDBJ/ENA/GenBank with the BioProject number PRJNA681740.

2.5. RNA Extraction and cDNA Synthesis. RNA was extracted from the *N. gonorrhoeae* isolates using TRIzol™ reagent (Invitrogen) with the PureLink™ RNA Mini Kit (ThermoFisher Scientific) and PureLink™ DNase (ThermoFisher Scientific) as per the manufacturer's instructions. The total RNA concentration was quantified using a nanodrop spectrophotometer, and samples were used only if the optical density at 260 nm (OD_{260/280}) was ~2.0. RNA integrity was confirmed using a bleach gel method [71]. One microgram of total RNA from each sample was reversed transcribed using the iScript™ Reverse Transcription Supermix for RT-qPCR (Bio-Rad) as per the manufacturer's instruction and reaction protocol. The total cDNA concentration was quantified, and samples were used only if the optical density at 260 nm (OD_{260/280}) was >1.8.

2.6. RNA Quantification by Real-Time PCR. Quantitative real-time PCR was performed for the primer sequences listed in Table 1 cDNA was diluted using a 1:10 ratio for real-time PCR analysis. Each PCR mixture (5 µl total volume) consisted of the respective primers (0.5 pmol/µl for *farB* and *mtrD*; 0.7 pmol/µl for 16S rRNA, *penA* and *macA*; 0.3 pmol/µl for all other primers), 2.5 µl PowerUp™ SYBR™ Green Master Mix (ThermoFisher Scientific, USA), 1 µg cDNA and nuclease-free water. Reactions were run in duplicate on the Quant Studio 5 (ThermoFisher, CA, USA) (1 cycle at 95°C, 2 min.), followed by 40 cycles consisting of denaturation at 95°C (15 sec.), annealing at 60°C (15 s), extension at 72°C (1 min). Followed by a melt curve stage (95°C, 15 s) ramp rate 1.6°C/s, 60°C (1 min) ramp rate 1.6°C/s, and 95°C (15 s) ramp rate 0.15°C/s. Amplification specificity was confirmed using melting curve analysis and gel electrophoresis. Serial dilutions of cDNA from total RNA

TABLE 1: Primers used for real-time qPCR.

Gene	Locus tag	Primer sequence (5'-3')	Amplicon size (bp)	Description
<i>penA</i>	NGO1542	penAF_ACCGAAAGACATCGTCGCCT penAR_CGTGGCACAAGCAAACCTGT	172	Penicillin-binding protein
<i>ponA</i>	NGO0099	ponAF_GGAGTGGGTCTGGTTGCCAT ponAR_GGCAATAACCGCATTCGCGCA	201	Penicillin-binding protein 1A
<i>pilQ</i>	NGO0094	pilQF_ACGAGGCTTTGGATTGCGAG pilQR_TTATGCTTTTTGCCGCGACCG	234	Type IV pilus secretin PilQ.
<i>rpsJ</i>	NGO1841	rpsJF_CCATCAGGCGAAATGGGTG rpsJR_CGCCCTGATTGACCGTTCTG	179	30S ribosomal protein S10
16S rRNA	NGO_r03 NGO_r06 NGO_r09 NGO_r12	16SrRNAF_AGCCGTAACACAGGTGCTGC 16S rRNAR_GACCATTGTATGACGTGTGAAGCC	209	16S ribosomal RNA
<i>gyrA</i>	NGO0629	gyrAF_TTGTGAGAAGCTGGATGACGG gyrAR_TGGACGAAGGCGAAACCTTG	185	DNA gyrase subunit A
<i>parC</i>	NGO1259	parCF_GGTTGCCGTCTATGCCTCCT parCR_CGCCTGCCTTCGCTTTCAAT	213	DNA topoisomerase IV subunit A
<i>parE</i>	NGO1333	parEF_GCCTTCGCGTTCCATCCAAG parER_GATGAACCCCGACCAGCTCA	166	DNA topoisomerase IV subunit B
23S rRNA	NGO_r02 NGO_r05 NGO_r08 NGO_r11	23SF_TGCTTCCAAGCCTTCCAC 23SR_GAATGGCGTAACGATGGC	171	23S ribosomal RNA
<i>mtrR</i>	NGO1366	mtrRF_CGTTGGACGGGCTGATTTGG mtrRR_CGCAGGCAGGGATGGTTTTTC	118	HTH-type transcriptional regulator MtrR
<i>mtrA</i>	NGO1250	mtrAF_GTGCCTTTTGGGCGGACAAT mtrAR_TCCGTCGTGGCTCAACACAT	173	Transcriptional activator of mtrCDE
<i>mtrC</i>	NGO1365	mtrCF_TCCACAACCACCTTGTCCCC mtrCR_GCGGTGCGAAAGATACCGTG	136	Cation/multidrug efflux protein
<i>mtrD</i>	NGO1364	mtrDF_CGTATTGCTGGACGGTTGCC mtrDR_GCACGCCATTTATCCGGGTG	242	Cation/multidrug efflux protein
<i>mtrE</i>	NGO1363	mtrEF_AGACGGCATTTGTTTGCCCG mtrER_ATTTGCTCGATGCGGAACGC	165	Multidrug transporter
<i>mtrF</i>	NGO1368	mtrFF_ACAGTCAATGGCTGGGCAA mtrFR_GAAATACGCACCGACGGCAG	99	Integral membrane protein. Newly described efflux pump
<i>macA</i>	NGO1440	macAF_TTCACGGTCAGCGACGGAAT macAR_CCCGTTCCGTTTGTGGCGAAT	115	Macrolide transport protein MacA
<i>macB</i>	NGO1439	macBF_ATCTGCCTGATGCTGTGCT macBR_CCGACGTGCTGATGCTTTGG	199	Macrolide ABC transporter ATP-binding protein/permease
<i>norM</i>	NGO0395	norMF_ATCGAAACGGTAGGCGAGCA norMR_AACCGGCAGACTTACCCAA	140	Multidrug efflux protein
<i>farA</i>	NGO1683	farAF_GCGGATTGCCCGAGGATTTTC farAR_GCTGAACCGCGAAGATGTGG	183	Multidrug resistance protein
<i>farB</i>	NGO1682	farBF_TGTTGCGGAATAGGGCGTGA farBR_CACTGTGCGACATGAAGGGC	170	EmrB/QacA subfamily multidrug transporter

(control strain WHO F) were performed for each target. These served as standard curves for quantitative analysis. The Quant Studio 5 (ThermoFisher, CA, USA) analysis software version 3.3 was used for quantitative analysis. The expression levels were calculated after normalization to a housekeeping gene (16S rRNA).

2.7. Statistical Analysis. Nonparametric statistical analysis and correlations were performed using GraphPad Prism v5.0

(Graphpad Software Inc. CA, USA) and IBM® SPSS Statistics v27. The differences between the groups (susceptible/nonsusceptible, mutations/no mutations, and males/females) were evaluated using *t*-tests. The regression analysis was performed to determine the relationship of susceptibility as the dependant variable to mRNA levels of antibiotic resistance-associated genes as the independent variables. For each drug, the regression model included all independent variables. A *p* -value <0.05 was considered to denote statistical significance. Using a receiver operating characteristic

(ROC) analysis (which assesses the accuracy of model predictions), cutoff values were calculated for genes associated with resistance for each drug.

3. Results

Resistance-to-penicillin, tetracycline, and ciprofloxacin were high in our isolates (supplementary Figure 2), also described in our previous paper [35]. All isolates were susceptible to spectinomycin, azithromycin, ceftriaxone, and cefixime. A total of 110 isolates were analysed to determine differences in mRNA levels between susceptible and nonsusceptible isolates. A subset of 61 isolates with similar MIC values (30 vaginal swabs and 31 urethral swabs) with similar MIC values were analysed to determine differences in mRNA levels between males and females and for differences in mRNA levels between isolates with and without resistance-associated mutations.

3.1. Comparison of Gene Expression Levels between Susceptible and Nonsusceptible Isolates. We found that for all drugs tested, expression levels between the two groups (susceptible and nonsusceptible) were significantly different (supplementary Table 2). For penicillin (*penA*, *ponA*, *pilQ*, *mtrR*, *mtrC*, *mtrD*, *mtrE*, *mtrA*, and *mtrF*) the *p* values ranged from 0.01–0.04 (except *mtrF*, *p* value 0.17). For ciprofloxacin (*gyrA*, *parC*, *parE*, and *norM*) the *p* values were ≤ 0.001 . For tetracycline (*rpsJ*, *mtrR*, *mtrC*, *mtrD*, *mtrE*, *mtrA*, and *mtrF*) the *p* values ranged from 0.001–0.04. For azithromycin (23S rRNA, *macA*, *macB*, *mtrR*, *mtrC*, *mtrD*, *mtrE*, *mtrA*, and *mtrF*) the *p* values ranged from ≤ 0.001 –0.01 (except *mtrC*, *p* value 0.1). For spectinomycin, the *p* value for 16S rRNA was ≤ 0.001 . For ESC (*penA*, *mtrR*, *mtrC*, *mtrD*, *mtrE*, *mtrA*, and *mtrF*) the *p* values ranged from ≤ 0.001 –0.05.

3.2. Comparison of Gene Expression Levels between Isolates with No Mutations Vs. Isolates with Mutations. The median expressions of antimicrobial and efflux pump genes (*farA*, *farB*, *gyrA*, *macA*, *macB*, *mtrA*, *mtrC*, *mtrD*, *mtrE*, *mtrF*, *mtrR*, *norM*, *parC*, *parE*, *penA*, *ponA*, *pilQ*, *rpsJ*, 16S rRNA, and 23S rRNA) associated with resistance were examined to determine any differences between isolates with mutations in the resistance-associated genes compared to isolates without mutations (supplementary Table 3). We found significant differences between the wildtype genes and isolates genes with mutations *mtrF*_V213I (*p* = 0.02), *gyrA*_S91F (*p* = 0.02), *gyrA*_D95G (*p* = 0.026), *parC*_S87N (*p* = 0.023), *parC*_V384I (*p* \leq 0.001), and *macA*_A8S (*p* = 0.01).

3.3. Comparison of Gene Expression Levels between Males and Females. The median expressions of antimicrobial target genes and efflux pump genes (*farA*, *farB*, *gyrA*, *macA*, *macB*, *mtrA*, *mtrC*, *mtrD*, *mtrE*, *mtrF*, *mtrR*, *norM*, *parC*, *parE*, *penA*, *ponA*, *pilQ*, *rpsJ*, 16S rRNA, and 23S rRNA) associated with resistance were examined to determine any differences between isolates from males and females. We found no

TABLE 2: Statistically significant logistic regression models of genes associated with AMR as determined by EUCAST MIC interpretation.

Drug	Model	Beta	Std. error	Wald	Df	Sig.
PEN	<i>penA</i>	-477.444	480.180	0.989	1	0.320
	<i>pilQ</i>	-45.427	409.199	0.012	1	0.912
	<i>ponA</i>	48.974	161.466	0.092	1	0.762
	<i>mtrR</i>	15.605	22.818	0.468	1	0.494
	<i>mtrC</i>	-21.799	9.640	5.113	1	0.024
	<i>mtrD</i>	40.099	207.809	0.037	1	0.847
	<i>mtrE</i>	38.026	94.177	0.163	1	0.686
	<i>mtrA</i>	6.592	7.251	0.827	1	0.363
	<i>mtrF</i>	7.687	13.078	0.345	1	0.557
	Constant	2.351	0.422	31.058	1	≤ 0.001
CIP	<i>gyrA</i>	22.691	10.286	4.867	1	0.027
	<i>parC</i>	92.723	155.843	0.354	1	0.552
	<i>parE</i>	-457.577	218.360	4.391	1	0.036
	<i>norM</i>	-95.040	97.960	0.941	1	0.332
		Constant	0.769	0.243	9.994	1
TET	<i>rpsJ</i>	-1431.586	734.579	3.798	1	0.047
	<i>mtrR</i>	-58.549	101.811	0.331	1	.565
	<i>mtrC</i>	-23.590	40.055	0.347	1	.556
	<i>mtrD</i>	415.541	449.943	0.853	1	.356
	<i>mtrE</i>	-179.181	257.407	0.485	1	.486
	<i>mtrA</i>	33.872	44.609	0.577	1	.448
	<i>mtrF</i>	24.805	38.481	0.415	1	.519
		Constant	4.886	1.182	17.075	1
AZ	23S	0.212	0.104	4.140	1	0.042
	<i>macA</i>	-104.209	68.197	2.335	1	0.126
	<i>macB</i>	429.998	317.542	1.834	1	0.176
	<i>mtrR</i>	-51.528	171.359	.090	1	0.764
	<i>mtrC</i>	43.816	30.898	2.011	1	0.156
	<i>mtrD</i>	-767.506	1316.124	.340	1	0.560
	<i>mtrE</i>	-2304.401	1446.997	2.536	1	0.111
	<i>mtrA</i>	-47.677	65.918	.523	1	0.470
	<i>mtrF</i>	162.321	126.611	1.644	1	0.200
	Constant	-3.426	1.545	4.916	1	0.027

Bold = significant resistance-associated marker for prediction of antimicrobial resistance in this setting. * The regression models for spectinomycin and ESC were not statistically significant due to a low number of data points in the resistant group, and therefore not included in this table.

significant difference between the expression levels of isolates from males compared to females. This was confirmed when we subdivided groups into male susceptible, male nonsusceptible, female susceptible, and female nonsusceptible.

3.4. Correlation of mRNA Expression Levels with Resistance. *penA*, *ponA*, *pilQ*, *mtrR*, *mtrC*, *mtrD*, *mtrE*, *mtrA*, *mtrF*, *gyrA*, *parC*, *parE* and *norM*, *rpsJ*, 16S, 23S, *macA*, and *macB* mRNA expression levels were determined for an association with resistance status using a logistic regression analysis (Table 2).

Binomial logistic regression was performed to ascertain the effects of *penA*, *ponA*, *pilQ*, *mtrR*, *mtrC*, *mtrD*, *mtrE*, *mtrA*, and *mtrF* on the likelihood that isolates were resistant to penicillin. The model explained 28.6% (Nagelkerke R²) of the variance in resistance-to-penicillin and correctly classified 81.0% of cases. Sensitivity was 96.3% and specificity

TABLE 3: Diagnostic performance of AMR-associated genes to detect antibiotic resistance using cutoff values determined by ROC analysis.

Drug	Gene	AUC	<i>p</i> value	Cutoff	Sens %	95% CI	Spec %	95% CI	Likelihood ratio
PEN	<i>penA</i>	0.63	0.027	<0.0018	84	74 to 91	38	21 to 56	1.35
	<i>ponA</i>	0.63	0.037	<0.0021	82	72 to 89	36	19 to 56	1.27
	<i>mtrR</i>	0.62	0.052	<0.0137	80	70 to 88	40	23 to 59	1.33
	<i>mtrC</i>	0.63	0.027	<0.0890	84	75 to 91	44	26 to 62	1.49
	<i>mtrD</i>	0.63	0.033	<0.0025	83	74 to 90	41	24 to 59	1.4
	<i>mtrE</i>	0.65	0.017	<0.0081	84	75 to 91	34	18 to 54	1.28
	<i>mtrA</i>	0.62	0.039	<0.1003	86	77 to 93	25	11 to 43	1.15
CIP	<i>gyrA</i>	0.66	0.003	<0.0518	83	73 to 91	33	20 to 48	1.24
	<i>parC</i>	0.65	0.004	<0.0032	85	74 to 92	29	17 to 43	1.19
	<i>parE</i>	0.67	0.001	<0.0033	88	78 to 94	33	20 to 48	1.3
	<i>norM</i>	0.65	0.006	<0.0084	93	85 to 98	29	17 to 43	1.3
TET	<i>rpsJ</i>	0.72	0.068	<0.0012	91	84 to 96	33	4 to 78	1.37
	<i>mtrR</i>	0.71	0.040	<0.0431	96	91 to 99	33	7 to 70	1.45
	<i>mtrC</i>	0.76	0.009	<0.1376	90	83 to 95	44	14 to 79	1.62
	<i>mtrA</i>	0.72	0.027	<0.1024	87	80 to 93	44	1 to 79	1.57
	<i>mtrF</i>	0.75	0.020	<0.1217	97	92 to 99	38	9 to 76	1.56
SPT	16S	0.96	0.115	<0.0454	100	2.5 to 100	96	91 to 99	24
AZ	23S	0.99	≤0.001	>7.7540	86	42 to 99	99	95 to 99	92.57
	<i>macA</i>	0.86	0.003	<0.0628	100	54 to 100	42	32 to 51	1.71
	<i>macB</i>	0.78	0.013	<0.0281	100	5 to 100	31	22 to 40	1.44
	<i>mtrR</i>	0.78	0.011	<0.0035	86	42 to 100	60	51 to 69	2.15
	<i>mtrC</i>	0.69	0.094	<0.0435	86	42 to 100	47	37 to 57	1.61
	<i>mtrD</i>	0.83	0.003	<0.0010	86	42 to 100	47	37 to 57	1.61
	<i>mtrE</i>	0.81	0.006	<0.0011	86	42 to 100	68	58 to 76	2.67
	<i>mtrA</i>	0.80	0.007	<0.0146	86	42 to 100	72	62 to 80	3.03
ESC	<i>mtrF</i>	0.80	0.009	<0.0070	86	42 to 100	64	5 to 73	2.36
	<i>penA</i>	1.0	0.086	<7.650e-005	100	2.5 to 100	99	95 to 99	114
	<i>mtrR</i>	0.89	0.023	<0.0014	100	29 to 100	80	71 to 87	4.91
	<i>mtrC</i>	0.87	0.028	<0.0170	100	29 to 100	78	69 to 85	4.56
	<i>mtrD</i>	0.96	0.007	≤0.001	100	29 to 100	91	84 to 96	11.4
	<i>mtrE</i>	0.94	0.01	≤0.001	100	29 to 100	87	79 to 92	7.53
	<i>mtrA</i>	0.92	0.014	<0.0070	100	29 to 100	89	81 to 94	8.77
<i>mtrF</i>	0.92	0.013	<0.0031	100	29 to 100	87	79 to 92	7.53	

Bold = significant resistance-associated marker for prediction of antimicrobial resistance in this setting.

was 29.2%. Of the predictor variables, *mtrC* was statistically significant ($p = 0.024$). The discrimination of this model, as determined by ROC curve analysis, is acceptable (AUC 0.8). The logistic regression model was statistically significant, $p < 0.009$. The regression analysis was used to ascertain the effects of *gyrA*, *parC*, *parE*, and *norM* on the likelihood that isolates were resistant-to-ciprofloxacin. The model explained 19% (Nagelkerke R²) of the variance in resistance-to-ciprofloxacin and correctly classified 65.8% of cases. Sensitivity was 90.1% and specificity was 30.6%. Of the predictor variables, *gyrA* and *parE* were statistically significant, $p = 0.027$ and 0.036 , respectively. The discrimination of this model, as determined by the ROC curve analysis, is acceptable (AUC 0.7). The logistic regression model was statistically significant, $p = 0.001$.

Regression analysis was used to ascertain the effects of 23S rRNA, *macA*, *macB*, *mtrR*, *mtrC*, *mtrD*, *mtrE*, *mtrA*, and *mtrF* on the likelihood that isolates were resistant to azithromycin. The model explained 67.9% (Nagelkerke R²) of the variance in resistance-to-azithromycin and correctly classified 94.9% of cases. Sensitivity was 42.9% and

specificity was 98.2%. Of the predictor variables, 23S rRNA was statistically significant ($p = 0.042$). The discrimination of this model, as determined by the ROC curve analysis, is outstanding (AUC 0.98). The logistic regression model was statistically significant, $p \leq 0.001$.

For tetracycline, spectinomycin, and ESC, the discrimination of the models was excellent (AUC >9) and correctly classified >98% of cases. However, due to a low number of data points in either the susceptible or resistant groups, the regression models for these drugs were not statistically significant.

3.5. ROC Analysis of qPCR Data. To determine the threshold (cutoff) of individual genes determined as drug-resistant, a ROC (receiver operating characteristic) analysis was performed. Using the AUC, cutoff, sensitivity, and specificity results (listed, respectively), we evaluated the qPCR assays as a tool to predict resistance to each drug (Table 3). Multiple resistance-associated genes for each antibiotic showed high sensitivities (82%–100%). The performance characteristics of

the significant markers, as determined by regression analysis, were as follows: *mtrC* (0.63; <0.0890; 84%; 44%), *gyrA* (0.66; <0.0518; 83%; 33%), *parE* (0.67; <0.0033; 88%; 33%), *rpsJ* (0.72; <0.0012; 91%; 33%), 16S rRNA (0.96; <0.0454; 100%; 96%), and 23S rRNA (0.99; >7.754; 86%; 99%).

4. Discussion

DNA-based diagnostic approaches which detect resistance-associated single nucleotide polymorphisms (SNPs) are commonly investigated for use in *N. gonorrhoeae* AMR diagnosis. These approaches require the detection of multiple known mutations to infer resistance to a particular drug. In this study, we considered the whole gene rather than SNPs, and investigated the expression of known antibiotic target genes and efflux pump genes and correlated gene expression with AMR. To determine if sex-specific environments contribute to the transcription of AMR genes, we compared expression levels from isolates with similar susceptibility profiles from males and females. Regression analysis was used to determine the strongest predictors of drug resistance in our population, and using a ROC analysis; we estimated cutoff values.

The antibiotic target genes in *N. gonorrhoeae* have been widely described [4, 12]. Alterations in antibiotic target genes are associated with increased MICs and resistance. Our analysis shows that expression levels of antibiotic target genes are significantly higher in susceptible isolates compared to nonsusceptible isolates. A recent RNA-based study identified candidate markers from the transcriptomes which were highly expressed in the susceptible isolates only [51]. The *mtrR* gene, which represses the MtrCDE efflux pump, was higher in the susceptible group. This emphasizes the role of *mtrR* in AMR. MtrR has a more diverse regulatory role than only the MtrCDE efflux pump. It has also been shown to regulate MtrF (inner membrane accessory protein for efficient drug efflux) and FarR (repressor of the farAB efflux pump) [72]. MtrR has also been described to play a role in the expression of two other genes involved in susceptibility, *ponA*, and *pilQ*. By increasing the expression of *ponA* (encodes penicillin binding protein) and repressing the expression of *pilQ* (channel for entry for penicillin) [72].

Mutations can interrupt cellular processes and often hold the key to understanding gene function. Mutations in target genes are associated with resistance; however, for most mutations, we did not see any significant difference in gene expression between isolates with mutations and isolates without mutations. We found significant differences between the wildtype genes and isolates genes with mutations *mtrF_V213I* (higher expression), *gyrA_S91F* (lower), *gyrA_D95G* (lower), *parC_S87N* (lower), *parC_V384I* (higher), and *macA_A8S* (lower). A combination of mutations and other factors contribute to increased MICs; however, in our cohort, the majority of resistance to penicillin and tetracycline is attributed to *bla_{TEM}* and *tetM*, respectively [35].

It was previously reported that *N. gonorrhoeae* transcriptional responses to infection differed in genital specimens from men and women, and AMR gene expression was

increased in men, with a higher expression of MtrCDE efflux pump-related genes, suggesting that the expression of AMR genes is driven by sex-specific environments [49]. While overall gene expression signatures may be sex-specific, we found that in our cohort of South African patients, there were no significant differences in expression of resistance-associated targets between isolates from men and women. In addition, the *farA* and *farB* genes which encode the FarAB efflux pump (export host-derived antimicrobials, including cationic antimicrobial peptides and long-chain fatty acids) [4], were similarly expressed. Based on this outcome, we found that while therapeutic strategies could be based on gender, when using a diagnostic assay, there was no need to streamline the gene target profile based on gender, and that the same targets can be used for AMR detection for specimens from males and females in our setting.

In this study, we determined thresholds of mRNA levels, which could be used for resistance prediction within a South African population. Using regression analysis, we then determined the strongest predictors associated with AMR status. *N. gonorrhoeae* AMR is associated with numerous resistance mechanisms. We found the most significant markers for AMR status prediction in this population to be *mtrC*, *gyrA*, *parE*, *rpsJ*, and 23S rRNA. Our approach provides thresholds with high sensitivity for each of the strongest predictors using ROC analysis and can be used as a rule-in test for resistance prediction.

A limitation of the study and proposed models was the lack of clinical isolates with resistance to spectinomycin, azithromycin, cefixime, and ceftriaxone. Future studies will include a larger data set. Another limitation is that this needs to be evaluated on clinical specimens direct from patients to establish sensitivity as well as time-to-result. Also, the strongest predictors for the antibiotic resistance detection were limited to the isolates data used to generate the regression equations and is valid for the local setting in which these strains were isolated. This enforces the need for continuous local surveillance of isolates. Similar regression analysis can be used to identify candidate markers for resistance prediction in different geographic areas.

5. Conclusion

Using real-time qPCR, we have identified that mRNA levels of potential candidate markers of resistance can be used for AMR testing of *N. gonorrhoeae*. Together with the ROC cutoff values, these can be explored further as a set of genetic markers of antimicrobial resistance in our setting. A larger-scale validation is required, and evaluation directly from clinical specimens. Identifying local candidate markers has the potential to be used as a near-patient test in addition to NAATs identification.

Data Availability

Whole-genome sequence data is available in DDBJ/ENA/GenBank with the BioProject number PRJNA681740.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This study was funded by the DST-NRF Centre of Excellence (CoE) in HIV Prevention grant (96354) and the National Health Laboratory Service Research Trust grant (19762). The funders had no role in study design, data collection, and interpretation or the decision to submit for publication. The authors acknowledge Prof P. Moodley for donating a subset of isolates, V. Maseko and the staff at National Health Laboratory Service Microbiology Department (Durban).

Supplementary Materials

Supplementary Figure 1. Confirmation of *Neisseria gonorrhoeae* isolates using real-time PCR. Supplementary Figure 2. Antibiotic susceptibility profile of *Neisseria gonorrhoeae* isolated from South Africa between 2013 and 2017. Supplementary Table 1. Results of presumptive and confirmatory identification tests for *Neisseria gonorrhoeae*. Supplementary Table 2. Comparison of mRNA expression levels between antibiotic susceptible and nonsusceptible *N. gonorrhoeae* isolates from South Africa. Supplementary Table 3. Comparison of mRNA expression levels between South African *N. gonorrhoeae* isolates with mutations and with no mutations. (*Supplementary Materials*)

References

- [1] WHO, *WHO Guidelines for the Treatment of Neisseria Gonorrhoeae*, World Health Organization, Geneva, Switzerland, 2016.
- [2] WHO, *Global Health Sector Strategy on Sexually Transmitted Infections, 2016–2021*, World Health Organization, Geneva, Switzerland, 2016.
- [3] “Sexually transmitted infections management guidELINES,” *Comprehensive STI Clinical Management Guidelines, 2021–2025: National Department of Health, South Africa*, vol. 70, 2018.
- [4] M. Unemo and W. M. Shafer, “Antimicrobial resistance in *Neisseria gonorrhoeae* in the 21st century: past, evolution, and future,” *Clinical Microbiology Reviews*, vol. 27, no. 3, pp. 587–613, 2014.
- [5] D. W. Eyre, D. De Silva, K. Cole et al., “WGS to predict antibiotic MICs for *Neisseria gonorrhoeae*,” *Journal of Antimicrobial Chemotherapy*, vol. 72, no. 7, pp. 1937–1947, 2017.
- [6] A. P. R. Costa-Lourenço, K. T. Barros dos Santos, B. M. Moreira, S. E. L. Fracalanza, and R. R. Bonelli, “Antimicrobial resistance in *Neisseria gonorrhoeae*: history, molecular mechanisms and epidemiological aspects of an emerging global threat,” *Brazilian Journal of Microbiology*, vol. 48, no. 4, pp. 617–628, 2017.
- [7] D. Golparian, W. M. Shafer, M. Ohnishi, and M. Unemo, “Importance of multidrug efflux pumps in the antimicrobial resistance property of clinical multidrug-resistant isolates of *Neisseria gonorrhoeae*,” *Antimicrobial Agents and Chemotherapy*, vol. 58, no. 6, pp. 3556–3559, 2014.
- [8] WHO, *Report on Global Sexually Transmitted Infection Surveillance*, World Health Organization, Geneva, Switzerland, 2018.
- [9] E. A. Torrone, C. S. Morrison, P.-L. Chen et al., “Prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: an individual participant data meta-analysis of 18 HIV prevention studies,” *PLoS Medicine*, vol. 15, no. 2, Article ID e1002511, 2018.
- [10] N. J. Garrett, F. Osman, B. Maharaj et al., “Beyond syndromic management: opportunities for diagnosis-based treatment of sexually transmitted infections in low- and middle-income countries,” *PLoS One*, vol. 13, no. 4, Article ID e0196209, 2018.
- [11] G. S. Hall, *Bailey & Scott’s Diagnostic Microbiology*, American Society for Clinical Pathology, Chicago, IL, USA, 2015.
- [12] M. Christodoulides, *Neisseria Gonorrhoeae: Methods and Protocols*, Springer, Berlin, Germany, 2019.
- [13] G. W. Procop, D. L. Church, G. S. Hall, and W. M. Janda, *Koneman’s Color Atlas and Textbook of Diagnostic Microbiology*, Jones & Bartlett Publishers, Burlington, MA, USA, 2020.
- [14] K. A. Workowski and G. A. Bolan, “Sexually transmitted diseases treatment guidelines-2015,” *MMWR Recommendations and Reports: Morbidity and Mortality Weekly Report Recommendations and Reports*, vol. 64, pp. 1–137, 2015.
- [15] WHO, *Global Action Plan to Control the Spread and Impact of Antimicrobial Resistance in Neisseria Gonorrhoeae*, Geneva, Switzerland, 2012.
- [16] R. E. Johnson, W. J. Newhall, J. R. Papp et al., “Screening tests to detect *Chlamydia trachomatis* and *Neisseria gonorrhoeae* infections—2002,” *Morbidity and Mortality Weekly Report Recommendations and Reports*, vol. 51, no. RR-15, pp. 1–38, 2002.
- [17] K. Adachi, J. D. Klausner, C. C. Bristow et al., “Chlamydia and gonorrhea in HIV-infected pregnant women and infant HIV transmission,” *Sexually Transmitted Diseases*, vol. 42, no. 10, pp. 554–565, 2015.
- [18] E. Trembizki, A.-M. G. Costa, S. N. Tabrizi, D. M. Whiley, and J. Twin, “Opportunities and pitfalls of molecular testing for detecting sexually transmitted pathogens,” *Pathology*, vol. 47, no. 3, pp. 219–226, 2015.
- [19] J. M. Marrazzo, J. C. Dombrowski, and K. H. Mayer, “Sexually transmitted infections in the era of antiretroviral-based HIV prevention: priorities for discovery research, implementation science, and community involvement,” *PLoS Medicine*, vol. 15, no. 1, Article ID e1002485, 2018.
- [20] C. E. Holley, T. Van Pham, H. M. Mezzadra, G. C. Willis, and M. D. Witting, “Overtreatment of gonorrhea and chlamydial infections in 2 inner-city emergency departments,” *American Journal of Emergency Medicine*, vol. 33, no. 9, pp. 1265–1268, 2015.
- [21] S. C. Sonkar, K. Wasnik, A. Kumar, P. Mittal, and D. Saluja, “Comparative analysis of syndromic and PCR-based diagnostic assay reveals misdiagnosis/overtreatment for trichomoniasis based on subjective judgment in symptomatic patients,” *Infectious diseases of poverty*, vol. 5, no. 1, pp. 42–10, 2016.
- [22] S. C. Sonkar, K. Wasnik, A. Kumar et al., “Evaluating the utility of syndromic case management for three sexually transmitted infections in women visiting hospitals in Delhi, India,” *Scientific Reports*, vol. 7, no. 1, pp. 1465–1469, 2017.
- [23] B. Moges, G. Yismaw, A. Kassu et al., “Sexually transmitted infections based on the syndromic approach in Gondar town, northwest Ethiopia: a retrospective study,” *BMC Public Health*, vol. 13, no. 1, pp. 143–145, 2013.

- [24] I. Gould, "Antibiotic resistance: the perfect storm," *International Journal of Antimicrobial Agents*, vol. 34, pp. S2–S5, 2009.
- [25] B. Suay-García and M. T. Pérez-Gracia, "Future prospects for *Neisseria gonorrhoeae* treatment," *Antibiotics*, vol. 7, no. 2, p. 49, 2018.
- [26] T. M. File, A. Srinivasan, and J. G. Bartlett, "Antimicrobial stewardship: importance for patient and public health," *Clinical Infectious Diseases*, vol. 59, pp. S93–S96, 2014.
- [27] E. L. Tsalik, E. Petzold, B. N. Kreiswirth et al., "Advancing diagnostics to address antibacterial resistance: the diagnostics and devices committee of the antibacterial resistance leadership group," *Clinical Infectious Diseases*, vol. 64, pp. S41–S47, 2017.
- [28] M. Unemo, M. M. Lahra, M. Cole et al., "World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts," *Sexual Health*, vol. 16, no. 5, pp. 412–425, 2019.
- [29] D. Golparian and M. Unemo, "Antimicrobial resistance prediction in *Neisseria gonorrhoeae*: current status and future prospects," *Expert Review of Molecular Diagnostics*, vol. 22, no. 1, pp. 29–48, 2022.
- [30] W. L. Veal, R. A. Nicholas, and W. M. Shafer, "Overexpression of the MtrC-MtrD-MtrE efflux pump due to an mtrR mutation is required for chromosomally mediated penicillin resistance in *Neisseria gonorrhoeae*," *Journal of Bacteriology*, vol. 184, no. 20, pp. 5619–5624, 2002.
- [31] M. W. Kivata, M. Mbuchi, F. Eyase et al., "Plasmid mediated penicillin and tetracycline resistance among *Neisseria gonorrhoeae* isolates from Kenya," *BMC Infectious Diseases*, vol. 20, no. 1, pp. 703–711, 2020.
- [32] F. Vernel-Pauillac, S. Nandi, R. A. Nicholas, and C. Goarant, "Genotyping as a tool for antibiotic resistance surveillance of *Neisseria gonorrhoeae* in New Caledonia: evidence of a novel genotype Associated with reduced penicillin susceptibility," *Antimicrobial Agents and Chemotherapy*, vol. 52, no. 9, pp. 3293–3300, 2008.
- [33] S.-G. Lee, H. Lee, S. H. Jeong et al., "Various penA mutations together with mtrR, porB and ponA mutations in *Neisseria gonorrhoeae* isolates with reduced susceptibility to cefixime or ceftriaxone," *Journal of Antimicrobial Chemotherapy*, vol. 65, no. 4, pp. 669–675, 2010.
- [34] P. A. Ropp, M. Hu, M. Olesky, and R. A. Nicholas, "Mutations in ponA, the gene encoding penicillin-binding protein 1, and a novel locus, penC, are required for high-level chromosomally mediated penicillin resistance in *Neisseria gonorrhoeae*," *Antimicrobial Agents and Chemotherapy*, vol. 46, no. 3, pp. 769–777, 2002.
- [35] N. Mitchev, R. Singh, M. Allam et al., "Antimicrobial resistance mechanisms, multilocus sequence typing, and NG-STAR sequence types of diverse *Neisseria gonorrhoeae* isolates in KwaZulu-natal, South Africa," *Antimicrobial Agents and Chemotherapy*, vol. 65, no. 10, Article ID e0075921, 2021.
- [36] M. Unemo, D. Golparian, and D. W. Eyre, *Antimicrobial Resistance in Neisseria Gonorrhoeae and Treatment of Gonorrhoea Neisseria gonorrhoeae*, Springer, Berlin, Germany, 2019.
- [37] M. Unemo, H. S. Seifert, E. W. Hook, S. Hawkes, F. Ndowa, and J.-A. R. Dillon, "Gonorrhoea," *Nature Reviews Disease Primers*, vol. 5, no. 1, pp. 1–23, 2019.
- [38] V. G. Allen, D. J. Farrell, A. Rebbapragada et al., "Molecular analysis of antimicrobial resistance mechanisms in *Neisseria gonorrhoeae* isolates from Ontario, Canada," *Antimicrobial Agents and Chemotherapy*, vol. 55, no. 2, pp. 703–712, 2011.
- [39] M. Ohnishi, D. Golparian, K. Shimuta et al., "Is *Neisseria gonorrhoeae* initiating a future era of untreatable gonorrhoea?: detailed characterization of the first strain with high-level resistance to ceftriaxone," *Antimicrobial Agents and Chemotherapy*, vol. 55, no. 7, pp. 3538–3545, 2011.
- [40] S. A. Morse, S. R. Johnson, J. W. Biddle, and M. C. Roberts, "High-level tetracycline resistance in *Neisseria gonorrhoeae* is result of acquisition of streptococcal tetM determinant," *Antimicrobial Agents and Chemotherapy*, vol. 30, no. 5, pp. 664–670, 1986.
- [41] M. Hu, S. Nandi, C. Davies, and R. A. Nicholas, "High-level chromosomally mediated tetracycline resistance in *Neisseria gonorrhoeae* results from a point mutation in the rpsJ gene encoding ribosomal protein S10 in combination with the mtrR and penB resistance determinants," *Antimicrobial Agents and Chemotherapy*, vol. 49, no. 10, pp. 4327–4334, 2005.
- [42] V. Donà, N. Low, D. Golparian, and M. Unemo, "Recent advances in the development and use of molecular tests to predict antimicrobial resistance in *Neisseria gonorrhoeae*," *Expert Review of Molecular Diagnostics*, vol. 17, no. 9, pp. 845–859, 2017.
- [43] X.-Z. Li, C. A. Elkins, and H. I. Zgurskaya, *Efflux-mediated Antimicrobial Resistance in Bacteria: Mechanisms, Regulation and Clinical Implications*, Springer, Berlin, Germany, 2016.
- [44] R. A. Alm, S. D. Lahiri, A. Kutschke et al., "Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in *Neisseria gonorrhoeae*," *Antimicrobial Agents and Chemotherapy*, vol. 59, no. 3, pp. 1478–1486, 2015.
- [45] C. Rouquette-Loughlin, S. A. Dunham, M. Kuhn, J. T. Balthazar, and W. M. Shafer, "The NorM efflux pump of *Neisseria gonorrhoeae* and *Neisseria meningitidis* recognizes antimicrobial cationic compounds," *Journal of Bacteriology*, vol. 185, no. 3, pp. 1101–1106, 2003.
- [46] C. E. Rouquette-Loughlin, J. T. Balthazar, and W. M. Shafer, "Characterization of the MacA–MacB efflux system in *Neisseria gonorrhoeae*," *Journal of Antimicrobial Chemotherapy*, vol. 56, no. 5, pp. 856–860, 2005.
- [47] N. Low and N. J. Broutet, "Sexually transmitted infections—research priorities for new challenges," *PLoS Medicine*, vol. 14, no. 12, Article ID e1002481, 2017.
- [48] N. Low and M. Unemo, "Molecular tests for the detection of antimicrobial resistant *Neisseria gonorrhoeae*: when, where, and how to use?" *Current Opinion in Infectious Diseases*, vol. 29, no. 1, pp. 45–51, 2016.
- [49] K. Nudel, R. McClure, M. Moreau et al., "Transcriptome analysis of *Neisseria gonorrhoeae* during natural infection reveals differential expression of antibiotic resistance determinants between men and women," *mSphere*, vol. 3, no. 3, pp. e00312–e00318, 2018.
- [50] Y.-h Zhao, X.-l Qin, J.-y Yang, Y.-w Liao, X.-z Wu, and H.-p Zheng, "Identification and expression analysis of ceftriaxone resistance-related genes in *Neisseria gonorrhoeae* integrating RNA-Seq data and qRT-PCR validation," *Journal of global antimicrobial resistance*, vol. 16, pp. 202–209, 2019.
- [51] C. B. Wadsworth, M. R. Sater, R. P. Bhattacharyya, and Y. H. Grad, "Impact of population structure in the design of RNA-based diagnostics for antibiotic resistance in *Neisseria gonorrhoeae*," 2019, <https://www.biorxiv.org/content/10.1101/537175v1>.

- [52] R. Singh, A. Kusalik, and J.-A. R. Dillon, "Bioinformatics tools used for whole-genome sequencing analysis of *Neisseria gonorrhoeae*: a literature review," *Briefings in Functional Genomics*, vol. 21, no. 2, pp. 78–89, 2021.
- [53] O. B. Harrison, C. Schoen, A. C. Retchless et al., "Neisseria genomics: current status and future perspectives," *Pathogens and disease*, vol. 75, no. 6, 2017.
- [54] D. H. Bergey, J. G. Holt, and N. R. Krieg, *Bergey's Manual of Systematic Bacteriology*, Williams & Wilkins, Philadelphia, PA, USA, 1984.
- [55] D. E. Wood and S. L. Salzberg, "Kraken: ultrafast metagenomic sequence classification using exact alignments," *Genome Biology*, vol. 15, no. 3, pp. R46–R12, 2014.
- [56] L. Sánchez-Busó, C. A. Yeats, B. Taylor et al., "A community-driven resource for genomic epidemiology and antimicrobial resistance prediction of *Neisseria gonorrhoeae* at Pathogenwatch," *Genome Medicine*, vol. 13, no. 1, pp. 1–22, 2021.
- [57] J. R. Papp, J. Schachter, C. A. Gaydos, and B. Van Der Pol, "Recommendations for the laboratory-based detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae*—2014," *MMWR Recommendations and reports: Morbidity and Mortality Weekly Report Recommendations and Reports/Centers for Disease Control*, vol. 63, p. 1, 2014.
- [58] C.-H. Liao, C.-C. Lai, M.-S. Hsu et al., "Antimicrobial susceptibility of *Neisseria gonorrhoeae* isolates determined by the agar dilution, disk diffusion and Etest methods: comparison of results using GC agar and chocolate agar," *International Journal of Antimicrobial Agents*, vol. 35, no. 5, pp. 457–460, 2010.
- [59] CLSI, "Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically," *Approved Standard—Ninth Edition*, vol. 32, no. 2, 2012.
- [60] "Breakpoint tables for interpretation of Mics and zone diameters," 2017, <https://www.eucast.org>.
- [61] C. H. O'Callaghan, A. Morris, S. M. Kirby, and A. H. Shingler, "Novel method for detection of β -lactamases by using a chromogenic cephalosporin substrate," *Antimicrobial Agents and Chemotherapy*, vol. 1, no. 4, pp. 283–288, 1972.
- [62] M. Unemo, D. Golparian, L. Sánchez-Busó et al., "The novel 2016 WHO *Neisseria gonorrhoeae* reference strains for global quality assurance of laboratory investigations: phenotypic, genetic and reference genome characterization," *Journal of Antimicrobial Chemotherapy*, vol. 71, no. 11, pp. 3096–3108, 2016.
- [63] S. A. M. Kwenda, Z. T. H. Khumalo, S. Mtshali, F. Mnyameni, and A. Ismail, "Jekeka: an automated easy-to-use pipeline for bacterial whole genome typing," 2020, <https://github.com/stanikae/jekeka>, 2020.
- [64] F. Krueger, "Trim Galore," <https://github.com/FelixKrueger/TrimGalore>, 2020.
- [65] A. Bankevich, S. Nurk, D. Antipov et al., "SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing," *Journal of Computational Biology*, vol. 19, no. 5, pp. 455–477, 2012.
- [66] T. Seemann, "Shovill," <https://github.com/tseemann/shovill>, 2020.
- [67] A. Mikheenko, A. Prjibelski, V. Saveliev, D. Antipov, and A. Gurevich, "Versatile genome assembly evaluation with QUAST-LG," *Bioinformatics*, vol. 34, no. 13, pp. i142–i150, 2018.
- [68] E. Zankari, R. Allesøe, K. G. Joensen, L. M. Cavaco, O. Lund, and F. M. Aarestrup, "PointFinder: a novel web tool for WGS-based detection of antimicrobial resistance associated with chromosomal point mutations in bacterial pathogens," *Journal of Antimicrobial Chemotherapy*, vol. 72, no. 10, pp. 2764–2768, 2017.
- [69] L. Sánchez-Busó, C. A. Yeats, B. Taylor et al., "A community-driven resource for genomic epidemiology and antimicrobial resistance prediction of *Neisseria gonorrhoeae* at Pathogenwatch," *Genome Medicine*, vol. 13, no. 1, pp. 61–22, 2021.
- [70] F. Sievers, A. Wilm, D. Dineen et al., "Fast, scalable generation of high-quality protein multiple sequence alignments using custal omega," *Molecular Systems Biology*, vol. 7, no. 1, p. 539, 2011.
- [71] P. S. Aranda, D. M. LaJoie, and C. L. Jorczyk, "Bleach gel: a simple agarose gel for analyzing RNA quality," *Electrophoresis*, vol. 33, no. 2, pp. 366–369, 2012.
- [72] J. P. Folster, V. Dhulipala, R. A. Nicholas, and W. M. Shafer, "Differential regulation of ponA and pilMNOPQ expression by the MtrR transcriptional regulatory protein in *Neisseria gonorrhoeae*," *Journal of Bacteriology*, vol. 189, no. 13, pp. 4569–4577, 2007.